Morgan Stanley (NYSE:MS) initiated coverage on Novartis (SIX:NOVN:SW) (NYSE: NVS) with an Underweight rating and set a price ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Investing.com -- 瑞士制药公司诺华周二宣布，已达成协议收购生物制药公司Anthos Therapeutics。 根据公司声明，此次收购将包括诺华支付9.25亿美元的首付款，以及最高可达21.5亿美元的额外付款。

瑞士制药巨头 诺华 （Novartis）周二表示，已同意以至多30.8亿美元的价格收购美国私人控股的临床阶段生物制药公司Anthos Therapeutics，以扩大其心血管药物管线。

Novartis said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular pipeline.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

The easiest way to invest in a diversified basket of European equities is via a mutual fund or exchange-traded fund that is indexed to that region's stock market. The U.S.-based ETF benchmarked to ...

Nestle's slumping share price is rattling shareholders and pension funds that have invested in the food giant, piling ...

中国国家药监局药品审评中心 (CDE)官网最新公示，诺华 (NVS.US)申报的1类新药PIT565获得一项新的临床试验默示许可，拟开发治疗系统性红斑狼疮 (SLE)。公开资料显示，这是诺华在研的一款抗CD3/CD19/CD2的三特异性抗体，此前已经在中国获批针对B细胞恶性肿瘤的IND。

Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating ...